FIELD: medicine.
SUBSTANCE: there is described thiomorpholine compound presented by formula 
(I) wherein the ring A represents benzene ring; the ring B represents benzene ring; R1 represents hydrogen atom, R2 represents C1-6-alkyl group; R3a and R3b are identical or different, each representing hydrogen atom or C1-6-alkyl group, and n represents an integer equal to 2, or its pharmaceutically acceptable salt. There is also described method for making the compound of formula (1), a pharmaceutical composition and application of the compound of formula (1) for making a medical product used for treatment and prevention of the disease chosen from inflammation, allergic diseases, pain, migraine, neuralgia, itch, cough, central nervous system diseases, alimentary organ diseases, nausea, vomiting and urological disorders.
EFFECT: compounds exhibits affinity to neurokinine-1 receptor.
6 cl, 4 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF PIPERIDINE, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, THEIR USING AND TREATMENT METHOD | 2003 |
|
RU2294927C2 |
| NEUROACTIVE COMPOUNDS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764702C2 |
| LOW-MOLECULAR MODULATORS OF PANTOTHENAKINASES | 2018 |
|
RU2797123C2 |
| CATALYSTS | 2015 |
|
RU2706004C2 |
| HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | 2011 |
|
RU2623427C2 |
| CONDENSED BICYCLIC COMPOUND | 2008 |
|
RU2468017C2 |
| ANTITUMOR EFFECT STRENGTHENING AGENT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | 2018 |
|
RU2799006C2 |
| OPTIONALLY CONDENSED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE DERIVATIVES SUITABLE FOR TREATING INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | 2015 |
|
RU2719422C2 |
| NOVEL PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND OR SALT THEREOF | 2016 |
|
RU2705579C2 |
| METHOD FOR PRODUCING FLUORINE-CONTAINING ORGANIC COMPOUND | 2021 |
|
RU2807182C1 |
